Arvinas Announces FDA Approval of VEPPANU (vepdegestrant) for the Treatment of ESR1m, ER+/HER2- Advanced Breast Cancer

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/23/2026

1. PRIM
2. ABBV
3. DPZ
4. ACN
5. IBM
6. META
7. PLTR
8. MSFT
9. MHTLY
10. NAVN

Go back to Arvinas Announces FDA Approval of VEPPANU (vepdegestrant) for the Treatment of ESR1m, ER+/HER2- Advanced Breast Cancer
(NASDAQ: ARVN) Delayed: 7.74 --0 (-0%)
Previous Close $7.74    52 Week High $ 
Open $7.74    52 Week Low $ 
Day High $7.74    P/E N/A 
Day Low $7.74    EPS $ 
Volume 4,881